Tri-Segmented Arenaviruses As Vaccine Vectors

Patent No. EP3218504 (titled "Tri-Segmented Arenaviruses As Vaccine Vectors") was filed by Universit DE Genve on Nov 12, 2015. The application was issued on Jul 22, 2020.

Patent Summary

Tri-segmented arenavirus vaccine that carries two foreign genes to safely deliver antigens without losing viral safety. The virus genome is split into three parts, with one segment holding a standard viral gene and the other two carrying different genes of interest like tumor or pathogen antigens. Engineered recombination rules ensure that if the virus tries to merge these segments during replication, the resulting virus cannot function, preventing dangerous mutations. This design allows the virus to replicate and spread while safely delivering therapeutic proteins, offering a versatile platform for vaccines and treatments.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
DR. URSULA SPRENZELApr 16, 2021WALCHER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3218504

UNIVERSIT DE GENVE
Application Number
EP15794900A
Filing Date
Nov 12, 2015
Status
Opposition Rejected
Sep 8, 2023
Publication Date
Jul 22, 2020